CD28 ligation increases macrophage suppression of T-cell proliferation

Cellular and Molecular Immunology

Volumn 9, Issue 4, 2012, Pages 341-349

  Silberman, Daniel ^a   Bucknum, Amanda ^a   Bartlett, Thomas ^a   Composto, Gabriella ^a   Kozlowski, Megan ^a   Walker, Amanda ^a   Werda, Amy ^a   Cua, Jackelyn ^a   Sharpe, Arlene H ^b   Somerville, John E ^c   Riggs, James E ^a  

^a RIDER UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

CD28; costimulation; macrophages; suppression

Indexed keywords

CD28 ANTIGEN; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME INHIBITION; FEMALE; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PERITONEAL CAVITY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD28; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CELLULAR MICROENVIRONMENT; IMMUNOSUPPRESSION; INTERFERON-GAMMA; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE II; RECEPTOR AGGREGATION; RECEPTOR CROSS-TALK; T-LYMPHOCYTES;

EID: 84863428218     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2012.13     Document Type: Article

References (67)

1. Schwartz R, Mueller D, Jenkins M, Quill H. T cell clonal anergy. Cold Spring Harbor Symp Quant Biol 1989; 54: 605-610.
2. Greenwald R, Freeman G, Sharpe A. The B7 family revisited. Ann Rev Immunol 2005; 23: 515-548.
3. Manicassamy S, Pulendran B. Dendritic cell control of tolerogenic responses. Immunol Rev 2011; 241: 206-227.
4. Composto G, Gonzalez D, Bucknum A, Silberman D, Taylor J, Kozlowski M et al. Peritoneal T lymphocyte regulation by macrophages. Immunobiology 2011; 216: 256-264.
5. Nagaraj S, Gabrilovich D. Myeloid-derived suppressor cells in human cancers. Cancer J 2010; 16: 348-353.
6. Hopken U, Lehmann I, Droese J, Lipp M, Schuler T, Rehm A. The ratio between dendritic cells and T cells determines the outcome of their encounter: Proliferation versus deletion. Eur J Immunol 2005; 35: 2851-2863.
7. Pollard J. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71-78.
8. Drake C, Jaffee E, Pardoll D. Mechanisms of immune evasion by tumors. Adv Immunol 2006; 90: 51-81.
9. Rabinovich G, Gabrilovich D, Sotomayor E. Immunosuppressive strategies that are mediated by tumor cells. Ann Rev Immunol 2007; 25: 267-296.
10. Denning T, Norris B, Medina-Contreras O, Manicassamy S, Geem D, Madan R et al. Functional specialization of intestinal dendritic cell and macrophage subsets that control Th17 and regulatory T cell responses are dependent on the T cell/APC ratio, source of mouse strain, and regional localization. J Immunol 2011; 187: 733-747.
11. Zhu B, Kennedy J, Wang Y, Sandoval-Garcia C, Cao L, Xiao S et al. Plasticity of Ly-6Chi myeloid cells in T cell regulation. J Immunol 2011; 187: 2418-2432.
12. Bronte V, Zanovello P. Regulation of immune responses by L-Arginine metabolism. Nat Rev Immunol 2005; 5: 641-654.
13. Matlack R, Yeh K, Rosini L, Gonzalez D, Taylor J, Silberman D et al. Peritoneal macrophages suppress T-cell activation by amino acid catabolism. Immunology 2006; 117: 386-395.
14. Hamilton M, Antiganano F, Rossum A, Boucher J, Bennewith K, Krystal G. TLR agonists that induce IFN-b abrogate resident macrophage suppression of T cells. J Immunol 2010; 185: 4545-4553.
15. Lagasse E, Weissman I. Flow cytometric identification of murine neutrophils and monocytes. J Immunol Meth 1996; 197: 139-150.
16. Leo O, Foo M, Sachs D, Samelson L, Bluestone J. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci 1987; 84: 1374-1378.
17. Gross J, Callas E, Allison J. Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol 1992; 149: 380-388.
18. Potter M. History of the BALB/c family. Curr Top Microbiol Immunol 1985; 122: 1-5.
19. Paigen K. One hundred years of mouse genetics: An intellectual history. I. The classical period (1902-1980). Genetics 2003; 163: 1-7.
20. Rochford R, Riggs J, Clavo A, Ernst D, Hobbs M. Differential effect of CD28 costimulation upon cytokine production by CD41 and CD81 T cells. Immunobiology 2004; 209: 513-522.
21. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008; 8: 467-477.
22. Quezada S, Peggs K, Simpson T, Allison J. Shifting the equilibrium in cancer immunoediting: From tumor tolerance to eradication. Immunol Rev 2011; 241: 104-18.
23. Bouaziz J-D, Yanaba K, Tedder T. RegulatoryBcells as inhibitors of immune responses and inflammation. Immunol Rev 2008; 224: 201-214.
24. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010; 127: 759-67.
25. Munn D. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counterregulation. Curr Opin Immunol 2006; 18: 220-225.
26. Balkwill F, Charles K, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211-217.
27. Martin-Orozco N, Dong D. Inhibitory costimulation and anti-tumor immunity. Semin Cancer Biol 2007; 17: 288-96.
28. Wherry J. T cell exhaustion. Nat Immunol 2011; 12: 492-499.
29. Krummel M, Sullivan T, Allison J. Superantigen response and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol 1996; 8: 519-523.
30. Perez V, van Parijs L, Biuckians A, Zheng X, Strom T, Abbas A. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997; 6: 411-417.
31. Yu X, Bidwell S, Martin P, Anasetti C. CD28-specific antibody prevents graft-versushost disease in mice. J Immunol 2000; 164: 4564-4568.
32. Tacke M, Clark G, Dallman M, Hunig Y. Cellular distribution and costimulatory function of rat CD28. Regulated expression during thymocyte maturation and induction of cyclosporine A sensitivity of costimulated T cell responses by phorbol ester. J Immunol 1995; 154: 5121-5127.
33. Dengler T, Szabo G, Sido B, Nottmeyer W, Zimmerman R, Vahl C et al. Prolonged allograft survival but not tolerance induction by modulating CD28 antibody JJ319 after high-responder heart transplantation. Transplantation 1999; 67: 392-398.
34. Haspot F, Seveno C, Dugast AS, Coulon F, Renaudin K, Usal C et al. Anti-CD28 antibody-induced kidney allograft tolerance related to tryptophan degradation and TCR-Class II-B71 regulatory cells. Am J Transplant 2005; 5: 2339-2348.
35. Guillonneau C, Seveno C, Dugast AS, Li XL, Renaudin K, Haspot F et al. 2007. Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Igtreated heart allograft recipients. J Immunol 2007; 179: 8164-8171.
36. Pandiyan P, Hege J, Krueger M, Quandt D, Brunner-Weinzierl C. High IFN-c production of individual CD8 T lymphocytes is controlled by CD152 (CTLA-4). J Immunol 2007; 178: 2132-2140.
37. Beyersdorf N, Ding X, Blank G, Dennehy K, Kerkau T, Hunig T. Protection from graftversus-host disease with a novel B7 binding site-specific mouse anti-mouse CD28 monoclonal antibody. Blood 2008; 112: 4328-4336.
38. Poirier N, Azimzadeh A, Zhang T, Dilek N, Mary C, Nguyen B et al. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med 2010; 2: 17ra10.
39. Chang J, Kim Y, Han S, Kang C. IFN-gamma-STAT 1 signal regulates the differentiation of inducible Treg: Potential role for ROS-mediated apoptosis. Eur J Immunol 2009; 39: 1241-1251.
40. Singh N, Yamamoto M, Takami M, Seki Y, Takezaki M, Mellor A et al. CD41CD251 regulatory T cell resist a novel form of CD28- and Fas-dependent p53-induced T cell apoptosis. J Immunol 2010; 184: 94-104.
41. Carrio R, Torroella-Kouri M, Libreros S, Garcia-Areas R, Iragavarapu-Charyulu V, Lopez D. Decreased accumulation of immune regulatory cells is correlated to the antitumor effect of IFN-c overexpression in the tumor. Int J Oncol 2011; 39: 1619-1627.
42. Lee S-W, Choi H, Eun S-Y, Fukuyama S, Croft M. Nitric oxide modulates TGF-bdirective signals to suppress Foxp31 regulatory T cell differentiation and potentiate Th1 development. J Immunol 2011; 186: 6972-6980.
43. Baban B, Chandler P, Sharma M, Pihkala J, Koni P, Munn D et al. IDO activates regulatory T cells and blocks their conversion into Th17-like cells. J Immunol 2009; 183: 2475-2483.
44. Dugast A-S, Vanhove B. Immune regulation by non-lymphoid cells in transplantation. Clin Exp Immunol 2009; 156: 25-34.
45. Wang R, Fang Q, Zhang L, Radvany L, Sharma A, Noben-Trauth N et al. CD28 ligation prevents bacterial toxin-induced septic shock in mice by inducing IL-10 expression. J Immunol 1997; 158: 2856-2861.
46. Carter N, Vasconcellos R, Rosser E, Tulone C, Munoz-Suano A, Kamanaka M et al. 2011. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol 186: 5569-5579.
47. Biswas S, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat Immunol 2010; 11: 889-896.
48. Geissmann F, Gordon S, Hume D, Mowat A, Randolph G. Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol 2010; 10: 453-460.
49. Hoechst B, Gamrekelashvili J, Manns M, Greten T, Korangy F. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood 2011; 117: 6523-6541.
50. Blumenthal R, Campbell D, Hwang P, DeKruyff R, Frankel L, Umetsu D. Human alveolar macrophages induce functional inactivation in antigen-specific CD4 T cells. J Allergy Clin Immunol 2001; 107: 258-264.
51. Borowski A, Boesteanu A, Mueller Y, Carafieds C, Topham D, Altman J et al. Memory CD81 T cells require CD28 costimulation. J Immunol 2007; 179: 6494-6503.
52. Curiel T, Wei S, Dong H, Alvarez X, Cheng P, Mottram P et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 5: 562-567.
53. Latchman Y, Liang S, Wu Y, Chernova T, RSobel R, Klemm M et al. PD-L1 deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Nat Acad Sci 2004; 101: 10691-10696.
54. Keir M, Butte M, Freeman G, Sharpe A. PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol 2008; 26: 677-704.
55. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, costimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365-1369.
56. Lukacs-Kornek V, Malhotra D, Fletcher A, Acton S, Elpek K, Tayalia P et al. Regulated release of nitric oxide by nonhematopoietic stroma controls expansion of the activated T cell pool in lymph nodes. Nat Immunol 2011; 12: 1096-1105.
57. Yamazaki T, Akiba H, Koyanagi A, Azuma M, Yagita H, Okumura K. Blockade of B7-H1 on macrophages suppresses CD41 T cell proliferation by augmenting IFN-g-induced nitric oxide production. J Immunol 2005; 175: 1586-1592.
58. Loke P, Allison J. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Nat Acad Sci 2003; 100: 5336-5341.
59. Collins A, Brodie D, Gilbert R, Laboni A, Manso-Sancho R, Walse B et al. The interaction properties of costimulatory molecules revisited. Immunity 2002; 17: 201-210.
60. Butte M, Keir M, Phamduy T, Sharpe A, Freeman G. Programmed death-ligand 1 interacts specifically with B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27: 111-122.
61. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4: 336-350.
62. Suntharalingam G, Perry M, Ward S, Brett S, Castello-Cortes A, Brunner M et al. Cytokine storm in a phase I trial of the anti-CD28 monoclonal antibody TGN1412. New Engl J Med 2006; 355: 1018-1028.
63. Hansel T, Kropshofer H, Singer T, Mitchell J, George A. The safety and side effects of monoclonal antibodies. Nat Rev Drug Disc 2010; 9: 325-338.
64. Stebbings R, Findlay L, Edwards C, Eastwood D, Bird C, NorthD et al. 'Cytokine Storm' in the phase I trial of monoclonal antibody TGN1412: Understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 2007; 179: 3325-3331.
65. St. Clair E. The calm after the cytokine storm: Lessons from the TGN1412 trial. J Clin Invest 2008; 118: 1344-1347.
66. Sandilands G, Wilson M, Huser C, Jolly L, Sands W, McSharry C. Were monocytes responsible for initiating the cytokine storm in the TGH1412 clinical trial tragedy? Clin Exp Immunol 2011; 162: 516-27.
67. Waldmann T. Effective cancer therapy through immunomodulation. Ann Rev Med 2006; 57: 65-81.